Radiopharmaceuticals are transforming cancer diagnosis and treatment by combining targeting molecules with radionuclides. However, radioactive decay degrade these critical pharmaceuticals, limiting their shelf-life and therapeutic effectiveness. Currently, many radiopharmaceutical candidates are in the pipeline of large and small enterprises in different stages of development. As hundreds of novel radiopharmaceuticals enter these pipelines, there is not only an opportunity for our invention but also a growing and urgent need to ensure that patients can be timely served with products that remain effective. We have developed an innovative formulation and method capable of preventing the degradation of radiopharmaceuticals regardless of the molecule or radionuclide used. This groundbreaking technology universally protects the integrity and efficacy of radiopharmaceuticals, significantly improving their stability during transportation from production facilities to clinical settings. By effectively eliminating radical-induced degradation, our solution ensures that healthcare providers can reliably administer highly potent and stable radiopharmaceutical therapies to patients, thanks to the ability to extend the shelf-life of these life-saving products.